31,243 Shares in Mural Oncology plc (NASDAQ:MURA) Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC purchased a new stake in shares of Mural Oncology plc (NASDAQ:MURA) in the second quarter, Holdings Channel.com reports. The fund purchased 31,243 shares of the company’s stock, valued at approximately $98,000.

Several other institutional investors have also recently bought and sold shares of MURA. BBR Partners LLC bought a new stake in shares of Mural Oncology during the second quarter worth $31,000. Rhumbline Advisers acquired a new position in Mural Oncology during the 2nd quarter worth about $34,000. Canada Pension Plan Investment Board acquired a new position in Mural Oncology during the 2nd quarter worth about $70,000. Dimensional Fund Advisors LP bought a new stake in Mural Oncology during the 2nd quarter worth about $71,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Mural Oncology in the 2nd quarter valued at about $84,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Trading Up 0.6 %

Shares of NASDAQ:MURA opened at $3.45 on Wednesday. The stock has a market capitalization of $58.39 million and a P/E ratio of -0.33. Mural Oncology plc has a 1-year low of $2.88 and a 1-year high of $17.00. The business has a 50-day moving average price of $3.26 and a two-hundred day moving average price of $3.46.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04. As a group, equities analysts predict that Mural Oncology plc will post -7.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Raymond James began coverage on shares of Mural Oncology in a research report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 target price on the stock. Rodman & Renshaw assumed coverage on Mural Oncology in a report on Friday, June 28th. They set a “buy” rating and a $15.00 price objective on the stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.